A fluoroquinolone (DR-3355) protects human lymphocyte cell lines from HIV-1-induced cytotoxicity.
HIV-1 infection of human CD4+ lymphocyte cell lines results in cell death. Treatment, but not pretreatment, of infected cells, with a fluoroquinolone antibiotic, DR-3355, protects a significant subfraction of cells from HIV-1-mediated cytolysis. All surviving cells have lost expression of the CD4 antigen, but do (MT-4) or do not (CEM) express viral antigens and produce infective virus. The rescued CEM and MT-4 cells are phenotypically stable and do not require continuous exposure to the drug for survival.
Nozaki-Renard
J
J
Department of Microbiology, Tokyo Medical College, Japan.
Iino
T
T
Sato
Y
Y
Marumoto
Y
Y
Ohta
G
G
Furusawa
M
M
D015704:CD4 Antigens / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000382:microbiology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D015242:Ofloxacin / Q000494:pharmacology*; D014779:Virus Replication
D015704:CD4 Antigens; D015242:Ofloxacin